Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of WJB001-based combination therapy in advanced solid tumors
CTR20251231Phase 2Active
- Sponsor
- Micro Biotech
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJB001 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), Serous endometrial adenocarcinoma, sponsored by Micro Biotech. Started Jul 2025; status: active.
02
Drugs
WJB001
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Serous endometrial adenocarcinoma
Beyond the preview
Go deeper on CTR20251231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251231.